|
Balance Sheet Cash Flow Statement 15 Skyline Dr. Hawthorne, NY 10532 NY Tel. 914-347-4300 Fax 914-347-4560 |
Type: Public
On the web:
http://www.acorda.com
Employees:
174
Employee growth: 20.8%
Acorda Therapeutics hopes its products really get on your nerves. The company is developing therapeutics that would restore neurological function for patients with spinal cord injury and other central nervous system disorders. The company markets and sells muscle relaxant Zanaflex in the US through a licensing agreement with Elan Corporation. Its lead drug candidate is Fampridine-SR, which enhances conduction in the myelin layer of nerves damaged by blunt trauma or from multiple sclerosis (MS). The drug is delivered by a sustained release system developed for the firm by Elan. Acorda's other drug candidates include drugs for MS and spinal cord injuries.
Key numbers for fiscal year ending December, 2008:
Sales: $47.8M
One year growth: 21.1%
Net income: ($74.3)M
Officers:
President CEO, and Director: Ron Cohen
CFO: David Lawrence
VP Corporate Communications: Tierney Saccavino
Competitors:
Biogen Idec
Mylan
Teva Pharmaceuticals
